Aethlon Medical (NASDAQ:AEMD) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Wednesday morning,Benzinga reports. They currently have a $7.00 target price on the medical equipment provider’s stock.

Separately, StockNews.com upgraded Aethlon Medical to a “sell” rating in a research report on Wednesday.

Aethlon Medical Trading Down 2.3 %

Shares of AEMD opened at $0.63 on Wednesday. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $1.85. The company has a market cap of $9.04 million, a PE ratio of -0.40 and a beta of 1.88. The stock has a 50-day moving average price of $0.65 and a 200-day moving average price of $0.48.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. As a group, analysts predict that Aethlon Medical will post -1.01 earnings per share for the current year.

Hedge Funds Weigh In On Aethlon Medical

Several institutional investors and hedge funds have recently made changes to their positions in AEMD. Renaissance Technologies LLC purchased a new stake in Aethlon Medical during the fourth quarter valued at about $25,000. Boothbay Fund Management LLC bought a new stake in Aethlon Medical during the 4th quarter valued at $186,000. Sassicaia Capital Advisers LLC purchased a new stake in Aethlon Medical during the 4th quarter valued at $31,000. Virtu Financial LLC bought a new stake in Aethlon Medical in the 4th quarter worth $81,000. Finally, Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Aethlon Medical in the fourth quarter valued at about $26,000. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.